Disclaimer: This information is provided for the use of physicians and other licensed health care practitioners only. This information is not for use by consumers. The information and or products are not intended for use by consumers or physicians as a means to cure, treat, prevent, diagnose or mitigate any disease or other medical condition. The information contained in this document is in no way to be taken as prescriptive nor to replace the physicians duty of care and personalised care practices.
Clearing up Confusion about Reverse T3: Part 1.
The Deiodinases and Thyroid Hormone Bioavailability
By Margaret Groves, ZRT Laboratory
Thyroid hormones are essential for the normal metabolic functioning of all tissues in the body, and a wide array of symptoms are therefore associated with abnormalities in thyroid hormone production and activation. Even when apparently adequate amounts of thyroxine are produced by the thyroid gland, thyroid function is profoundly affected by anything that disrupts conversion of thyroxine (T4) to the active thyroid hormone, triiodothyronine (T3). This conversion takes place primarily at the cellular level within tissues; only 20% of circulating T3 is generated by conversion of T4 within the thyroid gland itself.
The deiodinases - gatekeepers to intracellular thyroid hormone bioavailability
Both circulating and intracellular thyroid hormone levels are controlled by a complex, highly regulated system involving three iodothyronine deiodinases (known as D1, D2, and D3), which selectively remove iodine atoms to create the different hormones (see diagram). This system not only controls the relative amounts of both active and inactive hormone in the cell, but it also has the effect of conserving iodine, which has multiple intracellular functions (in the thyroid gland, the iodine is recycled for the synthesis of more thyroxine). A full discussion of the deiodinases and how they act as gatekeepers to intracellular thyroid hormone bioavailability and control the metabolic rate is outside the scope of this blog, but it is important to refer to high quality, recent reviews in peer-reviewed journals to understand this system properly [e.g., 1, 2, 3, 4].
1. The preferred substrate for D1 is rT3
2. D1 is downregulated by selenium deficiency, amiodarone, propranolol, propylthiouracil, dexamethasone, and ipodate; it is also reduced in non-thyroidal illness syndrome and critical illness.
3. D1 is uprregulated by T3
4. D2 resides in the endoplasmic reticulum where generated T3 can access the nucleus directly. D1 and D3 exist only on the cell membrane.
5. D3 is not normally expressed in adult tissues It is present in the placenta and newborn babies. It is reactivated in critical illness, starvation and the non-thyroidal illness syndrome.
What affects circulating levels of rT3 and T3?
Much experimental research into the deiodinase systems in various tissues has necessarily been done in animals other than humans, and when studying the research on reverse T3 (rT3) it is important to remember that humans are not the same as rodents. Bear in mind, for example, that hepatic D1 activity is the major contributor to circulating T3 in the rat, while in humans it is the D2 enzyme present in peripheral tissues that contributes the bulk of circulating T3.
In humans, the D1 enzyme has a much higher substrate preference for rT3 than for T4 , suggesting that its main function is to deiodinate rT3 to form T2, both conserving iodine and clearing rT3. In conditions in which D1 is downregulated, an increase in circulating rT3 is seen because the conversion of rT3 to T2 is significantly reduced, resulting in an accumulation of rT3. D1 is downregulated by selenium deficiency and in the non-thyroidal illness syndrome, as well as some cancers. It is also inhibited by some drugs, notably amiodarone, propranolol, propylthiouracil, dexamethasone, and ipodate. On the other hand, D1 is upregulated by T3, which restores the clearance of rT3 (via conversion to T2) and reduces the levels of circulating rT3 relative to T3. T3 therapy has therefore been used in some studies of critically ill patients in an attempt to restore intracellular thyroid function by upregulating the D1 deiodinase, but in general such treatment has not affected prognosis and it remains controversial. Most studies find that successful treatment of the underlying illness, as well as maintaining nutritional support and re-introducing mobility as soon as possible, naturally restores the T3/rT3 ratio to normal.
What is Reverse T3?
Reverse T3 (3,3’,5’-triiodothyronine, rT3) is a biologically inactive metabolite of thyroxine (T4) formed by selective deiodination; the active thyroid hormone T3 is formed by removal of an iodine atom in the outer ring of T4, while rT3 is formed by removal of an iodine atom in the inner ring of T4.
Relative amounts of each are determined by the activity of the respective deiodinase enzymes, which are regulated by hormonal and nutritional factors and physiological conditions.
Type 2 deiodinase – D2
Unlike D1 and D3 which are located in the plasma membrane of cells, D2 resides in the endoplasmic reticulum inside the cytosolic compartment, where the T3 generated by its activity can directly enter the nucleus and interact with thyroid receptors. The activity of D2 is therefore a primary determinant of intracellular T3 availability and thyroid receptor occupancy. While T3 generated from the activity of D1 is known to equilibrate rapidly with the plasma, D2-generated T3 remains within the cell and takes several hours to equilibrate with plasma. Unlike D1, D2 activity is increased in non-thyroidal illness.
Type 3 deiodinase – D3
The D3 enzyme is not normally expressed in adult tissues, whereas it is present in the placenta and the neonate where it protects the developing organism from excess thyroid hormone activity. It is, however, reactivated in conditions associated with a reduced metabolic rate, particularly starvation, severe carbohydrate restriction, tissue injury, reduced tissue oxygen supply, and critical illness (or the non-thyroidal illness syndrome), and also in chronic inflammation and some cancers. Its activity is increased in hyperthyroidism and decreased in hypothyroidism in the rat. D3 serves to inactivate T4 by converting it to rT3; this therefore limits the amount of T4 that can be used to form T3, reducing the availability of T3 to the thyroid receptors and thus slowing the metabolic rate. rT3 is rapidly cleared from the circulation, or further deiodinated to T2, which is now thought to exert some important biological effects at the thyroid receptors, albeit at about 100-fold reduced potency compared to T3 [5,6].
Want to learn about the role of reverse T3 in Thyroid Assessment?
1. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeöld A,Bianco AC. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29(7):898-938.
2. Maia AL, Goemann IM, Meyer EL, Wajner SM. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol. 2011;209(3):283-97.
3. Williams GR, Bassett JH. Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase. J Endocrinol. 2011;209(3):261-72.
4. Dentice M, Salvatore D. Deiodinases: the balance of thyroid hormone: local impact of thyroid hormone inactivation. J Endocrinol. 2011;209(3):273-82.
5. Orozco A, Navarrete-Ramírez P, Olvera A, García-G C. 3,5-Diiodothyronine (T2) is on a role. A new hormone in search of recognition. Gen Comp Endocrinol. 2014;203:174-80.
6. Leonard JL. Non-genomic actions of thyroid hormone in brain development. Steroids. 2008;73(9-10):1008-12.